Table 1 The correlation between clinical parameters and indicated positive T cell marker in ccRCC patients (n = 44)
From: The intrarenal landscape of T cell receptor repertoire in clear cell renal cell cancer
CD3 | CD4 | CD8 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Low expression | High expression | χ2 / P | Low expression | High expression | χ2 / P | Low expression | High expression | χ2 / P | ||
Tumour size | ||||||||||
< 5 cm | 18 (40.90%) | 9 (20.45%) | 9 (20.45%) | 0.063/0.802 | 9 (20.45%) | 9 (20.45%) | 0.254/0.614 | 8 (18.18%) | 10 (22.73%) | 0.376/0.540 |
≥ 5 cm | 26 (59.09%) | 14 (31.82%) | 12 (27.27%) | 15 (34.09) | 11 (25.00%) | 14 (31.82%) | 12 (27.27%) | |||
ISUP grade | ||||||||||
Grade 1 | 6 (13.64%) | 3 (6.82%) | 3 (6.82%) | 1.714/0.634 | - | 6 (13.64%) | 9.545/0.023 | 1 (2.27%) | 5 (11.36%) | 5.918/0.116 |
Grade 2 | 21 (47.73%) | 12 (27.27%) | 9 (20.45%) | 11 (25.00%) | 10 (22.73%) | 13 (29.55%) | 8 (18.18%) | |||
Grade 3 | 14 (31.82%) | 6 (13.64%) | 8 (18.18%) | 10 (22.73%) | 4 (9.09%) | 5 (11.36%) | 9 (20.45%) | |||
Grade 4 | 1 (2.27%) | - | 1 (2.27%) | 1 (2.27%) | - | 1 (2.27%) | - | |||
CK7 | ||||||||||
Absent | 41 (93.18%) | 21 (47.73%) | 20 (45.45%) | 0.931/0.335 | 22 (50.00%) | 19 (43.18%) | 0.846/0.358 | 21 (47.73%) | 20 (45.45%) | 0.931/0.335 |
Present | 1 (2.27%) | 1 (2.27%) | - | 1 (2.27%) | - | 1 (2.27%) | - | |||
CD10 | ||||||||||
Absent | 1 (2.27%) | 1 (2.27%) | - | 0.885/0.347 | 1 (2.27%) | - | 0.802/0.370 | 1 (2.27%) | - | 0.885/0.347 |
Present | 40 (90.91%) | 21 (47.73%) | 19 (43.18%) | 22 (50.00%) | 18 (40.91%) | 21 (47.73%) | 19 (43.18%) | |||
CD117 | ||||||||||
Absent | 35 (79.55%) | 18 (40.91%) | 17 (38.64%) | 0.129/0.720 | 20 (45.45%) | 15 (34.09) | 0.015/0.904 | 19 (43.18%) | 16 (36.36%) | 0.058/0.810 |
Present | 5 (11.36%) | 3 (6.82%) | 2 (4.55%) | 3 (6.82%) | 2 (4.55%) | 3 (6.82%) | 2 (4.55%) | |||
Vimentin | ||||||||||
Absent | 5 (11.36%) | 5 (11.36%) | - | 4.432/0.035 | 5 (11.36%) | - | 5.449/0.020 | 5 (11.36%) | - | 4.916/0.027 |
Present | 34 (77.27%) | 17 (38.64%) | 17 (38.64%) | 15 (34.09) | 19 (43.18%) | 16 (36.36%) | 18 (40.91%) | |||
E-Cadherin | ||||||||||
Absent | 5 (11.36%) | 2 (4.55%) | 1 (2.27%) | 0.257/0.612 | 1 (2.27%) | 2 (4.55%) | 1.008/0.315 | 2 (4.55%) | 1 (2.27%) | 0.103/0.748 |
Present | 35 (79.55%) | 18 (40.91%) | 17 (38.64%) | 22 (50.00%) | 13 (29.55%) | 20 (45.45%) | 15 (34.09) | |||
CA-IX | ||||||||||
Absent | 1 (2.27%) | 1 (2.27%) | - | 0.924/0.336 | 1 (2.27%) | - | 0.831/0.362 | 1 (2.27%) | - | 1.027/0.311 |
Present | 37 (84.09%) | 19 (43.18%) | 18 (40.91%) | 20 (45.45%) | 17 (38.64%) | 18 (40.91%) | 19 (43.18%) | |||
Pax-8 | ||||||||||
Absent | 3 (6.82%) | 3 (6.82%) | - | 2.265/0.132 | 2 (4.55%) | 1 (2.27%) | 0.146/0.702 | 1 (2.27%) | 2 (4.55%) | 0.521/0.471 |
Present | 29 (65.91%) | 16 (36.36%) | 13 (29.55%) | 16 (36.36%) | 13 (29.55%) | 16 (36.36%) | 13 (29.55%) | |||
P504S | ||||||||||
Absent | 9 (20.45%) | 3 (6.82%) | 6 (13.64%) | 2.918/0.088 | 5 (11.36%) | 4 (9.09%) | 0/0.984 | 4 (9.09%) | 5 (11.36%) | 0.558/0.455 |
Present | 29 (65.91%) | 19 (43.18%) | 10 (22.73%) | 16 (36.36%) | 13 (29.55%) | 17 (38.64%) | 12 (27.27%) | |||
TFE3 | ||||||||||
Absent | 32 (72.73%) | 17 (38.64%) | 15 (34.09) | 0.020/0.888 | 15 (34.09) | 17 (38.64%) | 0.792/0.374 | 17 (38.64%) | 15 (34.09) | 0.792/0.374 |
Present | 6 (13.64%) | 3 (6.82%) | 3 (6.82%) | 4 (9.09%) | 2 (4.55%) | 2 (4.55%) | 4 (9.09%) | |||
Ki-67 | ||||||||||
< 10% | 16 (36.36%) | 11 (25.00%) | 5 (11.36%) | 3.303/0.192 | 9 | 7 (15.91%) | 1.971/0.373 | 9 (20.45%) | 7 (15.91%) | 2.076/0.354 |
10–30% | 12 (27.27%) | 6 (13.64%) | 6 (13.64%) | 7 (15.91%) | 5 (11.36%) | 9 (20.45%) | 3 (6.82%) | |||
> 30% | 7 (15.91%) | 2 (4.55%) | 5 (11.36%) | 6 (13.64%) | 1 (2.27%) | 3 (6.82%) | 4 (9.09%) | |||